Company / Cash & Equivalents
Theravance Biopharma, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$167.8M
FY2025
5-year range
$37.8M / $298.2M
FY2021-FY2025
Trend
+344.0%
vs FY2024
Sector context
#104 of 207
Health Care
What the data says
Cash & Equivalents changed +344% YoY in FY2025, a notable deviation from the 9-year average annual change of +74%.
Based on SEC 10-K filings.
$168M in FY2025 with a 5-year CAGR of +15.5%.
Improved from $40M to $168M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.4%
- 5-Year CAGR
- +15.5%
- 10-Year CAGR
- -
Sector benchmark
#104 of 207 in Health CareTop 50% of 207This company $167.8M Sector average $669.5M
▼
-74.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.5%, indicating consistent growth.
- In FY2025, cash & equivalents increased 344.0% year-over-year.
- Ranks #104 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $167.8M | +344.0% |
| FY2024 | $37.8M | -4.4% |
| FY2023 | $39.5M | -86.7% |
| FY2022 | $298.2M | +231.5% |
| FY2021 | $90.0M | +10.4% |
| FY2020 | $81.5M | -78.4% |
| FY2019 | $378.0M | +324.8% |
| FY2018 | $89.0M | +0.0% |
| FY2017 | $89.0M | -74.2% |
| FY2016 | $344.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026